Search results
Showing 1 result for ta446
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)
This guidance has been updated and replaced by NICE technology appraisal guidance 524.
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)
This guidance has been updated and replaced by NICE technology appraisal guidance 524.